Publications by authors named "M Miyagi"
Purpose: Imeglimin is a novel oral antidiabetic agent that improves glucose tolerance. This study aimed to investigate the efficacy of combining imeglimin with dipeptidyl peptidase-4 inhibitor (DPP-4i), the most frequently prescribed first-line treatment for patients with type 2 diabetes (T2D) in Japan, to improve glycemic control.
Patients And Methods: Eleven patients with T2D treated with DPP-4i alone (6.
Antibody-drug conjugate (ADC) therapy has transformed treatment for several solid tumors, including small cell lung cancer (SCLC). However, significant challenges remain, including systemic toxicity, acquired resistance, and the lack of reliable biomarkers for patient selection. To enhance the effectiveness of ADC therapies in SCLC, we focused on target selection in this study by investigating the expression of ADC targets - SEZ6, DLL3, CD276, and TACSTD2 - in cell lines and patient samples.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on how osteosarcopenia—a combination of muscle and bone loss—affects dysphagia (difficulty swallowing) in older adults.
- Researchers reviewed health records from 211 patients aged 65 and older to analyze dysphagia severity using specific scoring systems.
- Findings revealed that patients with osteosarcopenia had more severe dysphagia compared to those without either condition, indicating a significant need for medical intervention.